Net Income - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.1 PLN -1.64% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Net Income Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Net Income Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Net Income
-zł93.9m
CAGR 3-Years
-32%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Net Income
-zł1.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-19%
M
Medicofarma Biotech SA
WSE:MDB
Net Income
-zł2.7m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Net Income
zł65.3m
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Net Income?
Net Income
-93.9m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Net Income amounts to -93.9m PLN.

What is Ryvu Therapeutics SA's Net Income growth rate?
Net Income CAGR 5Y
-27%

Over the last year, the Net Income growth was -25%. The average annual Net Income growth rates for Ryvu Therapeutics SA have been -32% over the past three years , -27% over the past five years .

Back to Top